CCCC:NSD-C4 Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 42.94

Change

-0.95 (-2.16)%

Market Cap

USD 2.13B

Volume

0.15M

Avg Analyst Target

USD 47.40 (+10.39%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; and BRAF V600E to treat melanoma, non-small cell lung cancer, colorectal cancer, and other solid malignancies, as well as RET to treat lung cancer, sporadic medullary thyroid cancers, and other solid malignancies. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffman-La Roche Ltd.; Biogen, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

+10.63 (+3.28%)

USD130.87B 38.30 29.43
BNTX BioNTech SE

+13.41 (+5.41%)

USD60.07B 13.82 10.18
REGN Regeneron Pharmaceuticals Inc

-9.76 (-1.76%)

USD59.17B 9.99 7.57
VRTX Vertex Pharmaceuticals Incorpo..

-0.97 (-0.53%)

USD47.16B 23.96 15.75
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

+2.38 (+0.66%)

USD33.45B N/A N/A
SGEN Seagen Inc

-0.76 (-0.44%)

USD31.43B 53.89 40.74
GMAB Genmab A/S

+0.07 (+0.16%)

USD29.05B 74.96 8.12
ALNY Alnylam Pharmaceuticals Inc

-4.66 (-2.23%)

USD24.79B N/A N/A
RPRX Royalty Pharma plc

-1.37 (-3.57%)

USD23.31B 31.09 11.82

ETFs Containing CCCC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 29.61% 81% B- 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.61% 81% B- 74% C
Trailing 12 Months  
Capital Gain 64.52% 81% B- 76% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 64.52% 81% B- 75% C
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 2.26% 36% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.26% 36% F 26% F
Risk Return Profile  
Volatility (Standard Deviation) 13.07% 98% A+ 87% B+
Risk Adjusted Return 17.30% 45% F 32% F
Market Capitalization 2.13B 85% B 76% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.86 38% F 29% F
Price / Cash Flow Ratio -31.62 84% B 84% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -32.69% 75% C 35% F
Return on Invested Capital -66.89% 36% F 12% F
Return on Assets -12.93% 80% B- 25% F
Debt to Equity Ratio 3.58% 66% D 81% B-
Technical Ratios  
Short Ratio 6.81 33% F 19% F
Short Percent 6.26% 42% F 28% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector